Genetic insights support PARP1 as a mediator in the protective association of ATP-citrate lyase inhibitors with melanoma
Abstract ATP-citrate lyase (ACLY) inhibitors emerge as a promising anti-cancer strategy, yet their causal effects across various cancer types remain unclear. Here, we employ a drug-target Mendelian randomization (MR) approach using four cis-expression quantitative trait loci for blood ACLY gene expr...
Saved in:
| Main Authors: | Jiawen Lu, Gloria Hoi-Yee Li, Jingyi Hu, Zhenqian Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-025-07860-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ATP Citrate Lyase <i>ClACLB-1</i> Facilitates Citrate Cleavage in Lemon
by: Chuang Lu, et al.
Published: (2024-12-01) -
ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis
by: Diyu Wang, et al.
Published: (2017-04-01) -
Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions
by: Nicola Ferri, et al.
Published: (2024-10-01) -
ATP citrate lyase is an essential player in the metabolic rewiring induced by PTEN loss during T-ALL development
by: Guillaume P. Andrieu, et al.
Published: (2025-04-01) -
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects
by: Liu Y, et al.
Published: (2025-03-01)